TCL Archive Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies November 28, 2014
TCL Archive FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment. September 28, 2001
TCL Archive Nine Saturation Program Planning Winners Names NCI May Reissue RFP Later This Year May 23, 1975
